Clinical Trials Browser

Phase 1 × Withdrawn × Urinary Bladder Neoplasms × Clear all

Urinary Bladder Neoplasms, Sarcoma, Endometrial Neoplasms

NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04054752 2023-11-02

Vaccine Response With NT-I7

Phase 1 Withdrawn

BreastGastrointestinalGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Colorectal Neoplasms

NCT03552796 2023-06-26

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Phase 1 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT05259397 2023-03-08

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04972253 2022-08-10

(BLASST)-3

Phase 1 Withdrawn

Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT04109092 2020-12-14

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Phase 1 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04073160 2020-07-07

TRIO Bladder

Phase 1 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT00880854 2019-11-15

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Phase 1 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT03007771 2017-10-06

Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia

Phase 1 Withdrawn

GastrointestinalGenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Pelvic Neoplasms, Rectal Neoplasms, Sarcoma

NCT00014287 2013-12-19

Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer

Phase 1 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

Clinical Trials

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Vaccine Response With NT-I7

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

(BLASST)-3

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

TRIO Bladder

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia

Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer